Solid Biosciences Inc.
SLDB Healthcare Biotechnology
Solid Biosciences Inc.’s revenue for fiscal 2022 (year ended December 2022) was $8.1 million. In the quarter to June 2026, EPS grew 9.52% and free cash flow fell 39.6%, each against the same quarter a year earlier.
Follow SLDB
Solid Biosciences Inc. (SLDB) EV/Sales
As of 16 October 2026, Solid Biosciences Inc. (SLDB) trades at a EV/Sales of 37.0×. Over the past ten years it has ranged from −16.1× (March 2023) to 109× (July 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | −14.6× | — |
| FY2021 | −1.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2022 | −14.6× | — |
| Jun 2022 | −4.7× | — |
| Mar 2022 | −3.7× | — |
| Dec 2021 | −1.5× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| OLMA Olema Pharmaceuticals, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 1.0× |
| WVE WAVE Life Sciences Ltd. compare | 2.2× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 2.4× |
| ZVRA Zevra Therapeutics, Inc. compare | 3.4× |
| SLDB Solid Biosciences Inc. | 37.0× |
| AVTX Avalo Therapeutics, Inc. compare | 82.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)